Consultation with
In 1984, Flo Hyman led the USA women's volleyball team to the Olympic gold medal. She was a head taller than her teammates and continued to play volleyball after the Olympic Games. In February 1985 she met her untimely death while competing. Her image on the cover of Sports Illustrated pointed out to many of us the dangers of sports participation for patients who have Marfan syndrome (previously undiagnosed in Ms. Hyman). Almost annually, a young athlete, usually playing basketball, collapses during competition or practice and dies from aortic rupture. The majority of tall individuals, of course, do not have Marfan syndrome. The purpose of this article is to discuss the differential diagnosis of tall stature and briefly review the restrictions and therapy pertinent to patients who have Marfan syndrome.
An individual is "tall" if he or she is greater than 2.5 standard deviations above the mean for age and gender. In adults this is more than 192 cm in males and more than 179 cm in females. The Table, which shows the major diseases associated with being tall, does not include the largest group of tall people-those who are "normal," usually associated with tall parents and relatives. Endocrine causes of tall stature include conditions that result from overproduction of growth hormone or thyroid hormone. Three of the diagnoses rely on chromosomal analyses: fragile X syndrome, Klinefelter syndrome (XXY), and XYY syndrome. Homocystinuria may be excluded by amino acid determination, especially among patients who have a negative family history and developmental delay.
Diagnosis of Marfan Syndrome
There is no consistent laboratory test by which Marfan syndrome can be diagnosed. Fibrillin is the affected protein, whose gene maps to chromosome 15q21. Several DNA mutations have been described that confirm the clinical diagnosis and allow for tracking of gene mutations in atrisk family members. Several major manifestations can aid in the diagnosis: ectopic lentis, dilation of the ascending aorta, aortic dissection, and dural ectasia (requires computed tomography or magnetic resonance imaging). If a patient has a family history of Marfan syndrome, it may be diagnosed by noting involvement of at least two of the following systems: skeletal, ocular, cardiovascular, pulmonary, skin, central nervous system, and at least one major manifestation. If the family history is negative, the diagnosis depends on involvement of the following: the skeletal and at least two other systems and at least one major manifestation. Marfan syndrome is transmitted as an autosomal dominant trait with a high degree of expressivity. About 30% of cases result from a new dominant mutation. The body habitus varies substantially, but the classic patient is tall, has arachnodactyly, hypermobile joints, scoliosis, a high arched palate, pectus deformity, and is thin (Figs 1 and 2 ). Arm span exceeds height, and upper-to-lower body ratio is lower than expected for age. Evaluations by a geneticist, cardiologist, and ophthalmologist may be needed to complete the diagnosis.
Cardiovascular Complications
The cardiac lesions that occur are the result of defective connective tissue that cannot withstand systemic blood pressure. The ascending aorta dilates progressively, thus losing tensile strength. Death usually occurs as a result of either a sudden elevation of blood pressure leading to aortic rupture or a rapid deceleration of the body leading to the severance of the weakened aorta from the heart. In these cases, death is rapid. There may be periods of aneurysmal increases in aortic size with small intimal and/or medial aortic tears; these cause significant chest pain. Aortic dissections may be chronic and subtle in older teenagers and young adults. The ascending aorta usually is replaced surgically when the aorta exceeds 55 to 60 mm. The replacement consists of a prosthetic valve sewn into a tube graft (composite graft), which replaces the dilated aortic segment. When the aortic root dilates significantly, the aortic leaflets no longer may oppose, and aortic regurgitation occurs, resulting in a decrescendo diastolic murmur. This extra volume, which must be ejected with each systole, tends to increase the rate of aortic dilation.
The mitral valve chordae tendineae also may be affected. As these lengthen progressively, the leaflets of the valve may prolapse and lead to mitral regurgitation. The leftsided cardiac chambers dilate, and contractility may be impaired. The physical signs of mitral prolapse and regurgitation are an ejection click at the apex followed by a holosystolic high-pitched murmur. The mitral valve is affected especially in infants who have the severe "infantile" form of Marfan syndrome.
Because tables of aortic root size for age in tall individuals were not available, we recruited 192 tall males and females who had no disease. We obtained echocardiographic measurements of the aorta and "regressed" this dimension with respect to height and body surface area. Independent of gender, the upper limit of the normal aortic root size was 1.9 cm/m 2 of body surface area.
Slowing Aortic Dilation
Virtually all of the mortality and most of the morbidity associated with Marfan syndrome results from the cardiovascular complications. At least 15 years ago, investigators at the Johns Hopkins Hospital began to try to slow the progression of aortic dilation by using oral beta blockade.
Initially propranolol was used; more recently, atenolol has been the drug of choice. Because the initial studies were encouraging, we undertook a joint study in which children whose aortic diameter exceeded the 95th percentile measurement were treated with atenolol. The investigators at Johns Hopkins used a dose of 1.2 ± 0.9 mg/kg per day. We were somewhat more aggressive, using 1.9 ± 0.6 mg/kg per day (P < .008 vs Hopkins dose). A control group of 13 who did not receive beta-blockers was followed clinically at Hopkins. The rate of dilation of the aortic root differed significantly when controls (2.1 ± 1.6 mm/yr increase) were compared with patients treated at Hopkins (1.1 ± 1.1 mm/yr) or at our institution (0.7 ± 1.8 mm/yr). The higher dose of medications tended to lead to a lower rate of aortic dilation (P > 0.05). More patients are needed to determine the optimal dosage of beta blocker for minimal aortic root growth. During the past decade of beta-blockade use, the rate of surgical intervention has declined significantly. At our institution, only one medication "non-complier" required surgery. A precipitous decline in emergency surgery has been noted at Johns Hopkins.
The age at which beta blockade should be started is debatable. Several institutions begin therapy during infancy. Our policy has been to wait until: 1) the aorta exceeds the 95th percentile or 2) a rapid rate of dilation is observed. We give the atenolol either bid or tid to reduce side effects from the dose of 2 mg/kg per day. Some individuals who have Marfan syndrome do not have a significantly abnormal aortic wall; they are at a low risk for aneurysm, dissection, or rupture and may never need treatment.
Sports Restrictions
Patients who have Marfan syndrome with aortic enlargement may not 
